AKT1 and cancer: Isorhamnetin has also been demonstrated to inhibit the PI3K-AKT-mTOR pathway (phosphatidylinositol 3-kinase, protein kinase B, and the mammalian target of rapamycin), which in turn inhibits the proliferation of cancer cells by inducing cell cycle arrest at the G2/M phase.